Acute myocardial infarction (MI) is defined as a rise and/or fall in cardiac troponins (cTn) with at least one value above the 99th percentile upper reference limit (URL) in the context of symptoms or clinical evidence of myocardial ischemia. The URL is based on measurements in a healthy reference population. Currently, a sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women. Reportedly, healthy men have twofold the troponin level compared to healthy women, suggesting that the use of a uniform URL for troponins may lead to the under-diagnostication of acute MI in women and potentially over-diagnostication in men. The purpose of the DANSPOT study is to evaluate the clinical effect on diagnosis, treatment and outcomes in men and women presenting with acute MI of implementing international guidelines recommendations of sex-specific 99th percentile URLs for troponin into clinical practice. First, to determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed up for 12 months after their first troponin measurement during the index admission. The hypothesis of the DANSPOT study is that implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI.
The present use of non-sex specific diagnostic cut-off levels of troponins in the diagnosis of acute myocardial infarction (MI) leads to under-diagnostication of acute MI in women and over-diagnostication in men. The purpose of this study is to document this through a randomized nationwide clinical implementation of population and sex-specific cut-off levels. Coronary artery disease (CAD) is globally the leading cause of mortality for men and women. The latest consensus statement defines myocardial infarction as 1) a rise and/or fall in cardiac troponins with 2) at least one value above the 99th percentile upper reference limit (URL) in the context of 3) symptoms or clinical evidence of myocardial ischemia. Thus, levels of cardiac troponins play a key role in the diagnostic work-up in general. Currently, uniform manufacturer-provided URLs, defined by the 99th percentile of cardiac troponins in a healthy reference population, is applied in Danish hospitals as a diagnostic cut-off for acute MI for both men and women. Lower levels of cardiac troponins are seen in healthy women as compared to healthy men, i.e. twice as high levels are seen in men. On this basis the clinical use of one uniform 99th percentile URL for cardiac troponins - i.e. applying the same diagnostic levels for men and women - may lead to a systematic under-diagnostication of acute MI in women and potentially an over-diagnostication of acute MI in men. Accordingly, the use of sex-specific 99th percentile URL of cardiac troponins are now recommended in recent guidelines by international cardiological societies, but this remains to be introduced in clinical practice. The 99th percentile URLs for cardiac troponins currently used in Danish Hospitals are provided by the manufacturer of each specific assay based on blood samples from a healthy reference population collected by the manufacturer. Studies have shown that the 99th percentile value is dependent on patient sex as well as on the reference population selected and the definition for "healthy" used in these studies. It is well known that the 99th percentile URL should stem from a local reference population. This recommendation has never been implemented in Denmark. The overall purpose of the study is to evaluate the clinical effect of implementing population and sex-specific 99th percentile URL for cardiac troponins in Denmark. To determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from healthy Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed up for 12 months after their first troponin measurement during the index admission. The clinical significance of sex-specific 99th percentile URLs for troponin remains poorly investigated and, for the same reason, not yet implemented in Denmark or many other countries. The basic hypothesis of the DANSPOT study is that the implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI. This would be guideline-defining for implementing sex-specific cutoffs for cardiac troponin in Denmark and internationally, as recommended by professional cardiological societies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
4,865
The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
Hospital of Southern Jutland
Aabenraa, Denmark
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Bispebjerg & Frederiksberg Hospital
Bispebjerg, Denmark
Rigshospitalet (Blegdamsvej)
Copenhagen Ø, Denmark
Sydvestjysk Sygehus
Esbjerg, Denmark
Glostrup University Hospital
Glostrup Municipality, Denmark
Gødstrup Regional Hospital
Gødstrup, Denmark
Herlev & Gentofte Hospital
Herlev, Denmark
C Torp-Pedersen
Hillerød, Denmark
...and 12 more locations
A composite endpoint of: 1) readmission for myocardial infarction 2) readmission for unplanned revascularisation (PCI or CABG) 3) all cause mortality All events must occur within 12 months of the first troponin measurement during the index admission
We will compare the occurrence of the primary outcome separately in men and women within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. For individuals included in the primary cohort, all readmissions within the 12-month follow-up period will be adjudicated by an endpoint committee to identify type 1, type 2, and type 4b myocardial infarction, as well as unplanned coronary revascularization. All-cause mortality will be ascertained from national patient data extracts. For the diagnosis of type 2 infarctions, we will utilize the criteria established by Saaby et al. Unplanned coronary revascularization is defined as any percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) performed after discharge from the index admission, in patients without coronary angiography or cardiac CT performed or planned during the index admission, leading to planned revascularization.
Time frame: The 12-month period starting from the first troponin measurement during the index admission.
All-cause mortality within 12 months
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. All-cause mortality within follow-up will be identified through patient data extracts. Follow-up is defined as the 12-month period starting from the first troponin measurement during the index admission.
Time frame: Within 12 months from the first troponin measurement during the index admission
Non-fatal myocardial infarction (MI) occurring during any readmission within 12 months
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Non-fatal MI during readmissions within follow-up will be identified through endpoint adjudication. Follow-up is defined as the 12-month period starting from the first troponin measurement during the index admission.
Time frame: Within 12 months from the first troponin measurement during the index admission
Unplanned coronary revascularization (PCI or CABG) performed during any readmission within 12 months
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Unplanned coronary revascularization during readmissions within follow-up will be identified through endpoint adjudication. Follow-up is defined as the 12-month period starting from the first troponin measurement during the index admission.
Time frame: Within 12 months from the first troponin measurement during the index admission
Non-fatal myocardial infarction (MI) occurring during the index admission
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Non-fatal MI during the index admission will be identified from patient data extracts.
Time frame: During index admission
Myocardial injury occurring during the index admission
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Myocardial injury during the index admission will be identified through patient data extracts.
Time frame: During index admission
Coronary angiography or coronary computed tomography performed during the index admission
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Coronary angiography and coronary computed tomography performed during the index admission will be identified through patient data extracts.
Time frame: During index admission
Coronary revascularization (PCI or CABG) performed during the index admission or planned during the index admission and subsequently performed within 3 months
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Coronary revascularization performed during the index admission, or planned during the index admission and subsequently performed within 3 months, will be identified using patient data extracts. Follow-up is defined as the 12-month period starting from the first troponin measurement during the index admission.
Time frame: During the index admission or within 3 months of discharge
Coronary angiography or coronary computed tomography performed during the index admission without subsequent planned coronary revascularization within 3 months
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. Coronary angiography and coronary computed tomography performed during the index admission without subsequent planned coronary revascularization within 2 months will be identified through patient data extracts. Follow-up is defined as the 12-month period starting from the first troponin measurement during the index admission.
Time frame: During the index admission or within 3 months of discharge
Length of stay during the index admission in the primary cohort
Secondary endpoints will be evaluated separately in women and men within the primary cohort before and after implementation of the new sex-specific diagnostic thresholds. The length of stay during the index admission will be identified from patient data extracts.
Time frame: During index admission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.